Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharma entities : Cocrystal pharma, inc. save search
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Published: 2024-03-28 (Crawled : 12:00) - globenewswire.com
COCP | $1.562 2.9K
|
Health Technology
|
| O: 2.68%
H: 13.73%
C: -8.5%
pharma antiviral financial results
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
Published: 2024-03-19 (Crawled : 12:00) - globenewswire.com
COCP | $1.562 2.9K
|
Health Technology
|
| O: 1.35%
H: 0.0%
C: -5.33%
cc-4234 fda pharma influenza cc-42344
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
Published: 2024-01-04 (Crawled : 13:00) - globenewswire.com
COCP | $1.562 2.9K
|
Health Technology
|
| O: 0.56%
H: 2.78%
C: -0.56%
pharma antiviral update
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
Published: 2023-12-06 (Crawled : 13:00) - globenewswire.com
COCP | $1.562 2.9K
|
Health Technology
|
| O: -0.3%
H: 4.76%
C: 0.3%
cc-4234 pharma influenza study cc-42344
Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
Published: 2023-11-29 (Crawled : 13:00) - globenewswire.com
COCP | $1.562 2.9K
|
Health Technology
|
| O: -2.17%
H: 5.56%
C: 2.78%
cc-4234 pharma west antiviral vaccine congress world influenza cc-42344
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023
Published: 2023-11-27 (Crawled : 13:00) - globenewswire.com
COCP | $1.562 2.9K
|
Health Technology
|
| O: 10.96%
H: 11.11%
C: 5.56%
pharma conference
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
Published: 2023-11-13 (Crawled : 13:00) - globenewswire.com
COCP | $1.562 2.9K
|
Health Technology
|
| O: -4.74%
H: 4.97%
C: 3.87%
pharma drug antiviral financial results
Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
Published: 2023-11-09 (Crawled : 13:00) - globenewswire.com
COCP | $1.562 2.9K
|
Health Technology
|
| O: 0.0%
H: 4.05%
C: 4.05%
cc-4234 pharma west antiviral vaccine congress world influenza cc-42344
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
Published: 2023-10-31 (Crawled : 12:00) - globenewswire.com
COCP | $1.562 2.9K
|
Health Technology
|
| O: -1.52%
H: 10.15%
C: 6.87%
cc-4234 pharma authorization influenza trial cc-42344
Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus
Published: 2023-09-28 (Crawled : 12:00) - globenewswire.com
COCP | $1.562 2.9K
|
Health Technology
|
| O: 0.0%
H: 6.12%
C: -0.51%
cdi-988 pharma norovirus study
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference
Published: 2023-09-05 (Crawled : 12:00) - globenewswire.com
COCP | $1.562 2.9K
|
Health Technology
|
| O: -9.63%
H: 4.04%
C: -6.36%
pharma conference global
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
Published: 2023-08-14 (Crawled : 12:00) - globenewswire.com
COCP | $1.562 2.9K
|
Health Technology
|
| O: -1.75%
H: 9.64%
C: 7.5%
pharma drug antiviral financial results
Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead
Published: 2023-08-08 (Crawled : 12:00) - globenewswire.com
COCP | $1.562 2.9K
|
Health Technology
|
| O: 3.89%
H: 7.86%
C: 3.37%
cdi-988 pharma norovirus
Cocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988
Published: 2023-05-31 (Crawled : 12:01) - globenewswire.com
COCP | $1.562 2.9K
|
Health Technology
|
| O: 0.45%
H: 2.23%
C: -3.57%
cdi-988 pharma approval study
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
Published: 2023-05-15 (Crawled : 12:00) - globenewswire.com
COCP | $1.562 2.9K
|
Health Technology
|
| O: -2.64%
H: 8.14%
C: -2.71%
pharma drug antiviral financial results
Cocrystal Pharma Presents New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference
Published: 2023-05-04 (Crawled : 20:00) - globenewswire.com
COCP | $1.562 2.9K
|
Health Technology
|
| O: 0.0%
H: 2.63%
C: 1.19%
cc-4234 pharma conference antiviral influenza group study cc-42344
Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors
Published: 2023-04-24 (Crawled : 14:00) - biospace.com/
PGEN | $1.405 0.36% 400K
|
Health Technology
|
| O: 0.0%
H: 1.64%
C: -4.92%
COCP | $1.562 2.9K
|
Health Technology
|
| O: 0.4%
H: 5.62%
C: 5.62%
pharma
Cocrystal Pharma to Present New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference
Published: 2023-04-18 (Crawled : 13:00) - biospace.com/
COCP | $1.562 2.9K
|
Health Technology
|
| O: -2.76%
H: 10.48%
C: 4.3%
cc-4234 pharma conference antiviral influenza group study cc-42344
Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Published: 2023-04-10 (Crawled : 13:00) - biospace.com/
COCP | $1.562 2.9K
|
Health Technology
|
| O: 11.4%
H: 12.56%
C: 1.4%
pharma nasdaq
Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs
Published: 2023-03-29 (Crawled : 14:00) - biospace.com/
COCP | $1.562 2.9K
|
Health Technology
|
| O: 2.47%
H: 2.46%
C: -0.79%
pharma drug antiviral financial results
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CSSE 4 | $0.3831 151.54% 190M
|
Consumer Services
CZOO | $11.04 121.24% 11M
|
LICN | $0.9107 62.63% 14M
|
BOF | $1.87 59.83% 100M
|
AMST | $3.18 59.0% 67M
|
Technology Services
MTC | $3.31 47.77% 7.7M
|
Technology Services
MULN | News | $3.915 43.41% 12M
|
Information
WIMI | $1.04 43.37% 17M
|
Technology Services
SKIL 4 | $8.045 40.89% 230K
|
Information
RILY | $30.01 38.17% 11M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.